Innate Pharma Gestione

Gestione criteri di controllo 4/4

Innate Pharma's Il CEO è Herve Brailly, nominato in Jan1999, ha un mandato di 25.58 anni. possiede direttamente 0.91% delle azioni della società, per un valore di € 1.52M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 4.5 anni e 5.8 anni.

Informazioni chiave

Herve Brailly

Amministratore delegato

€100.0k

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	25.8yrs
Proprietà del CEO	0.9%
Durata media del management	4.6yrs
Durata media del Consiglio di amministrazione	5.9yrs

Aggiornamenti recenti sulla gestione

Recent updates

AMMINISTRATORE DELEGATO

Herve Brailly (63 yo)

25.8yrs

Mandato

€100,000

Compensazione

Dr. Herve Brailly, Ph.D. Co-Founded Innate Pharma S.A in 1999 and served as its Chairman of Supervisory Board since December 31, 2016 until January 1, 2024 and serves as its Interim CEO and Chairman of the...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Herve Brailly	Co-Founder	25.8yrs	€100.00k	0.91% € 1.3m
Yannis Morel	Executive VP	9.4yrs	€599.92k	0.24% € 330.1k
François Romagné	Founder	no data	Nessun dato	Nessun dato
Eric Vivier	Founder	6.8yrs	Nessun dato	0.26% € 357.4k
Marc Bonneville	Founder	no data	Nessun dato	Nessun dato
Jean Fournié	Founder	no data	Nessun dato	Nessun dato
Alessandro Moretta	Founder	no data	Nessun dato	Nessun dato
Frederic Lombard	Senior VP & CFO	3.5yrs	Nessun dato	0.014% € 19.3k
Sonia Quaratino	Executive VP	less than a year	Nessun dato	Nessun dato
Arvind Sood	Executive VP	less than a year	Nessun dato	Nessun dato
Henry Wheeler	Vice President of Investor Relations & Communication	1.8yrs	Nessun dato	0.0039% € 5.4k
Odile Belzunce	Vice President of Compliance & Operations	5.8yrs	Nessun dato	0.077% € 105.8k

4.6yrs

Durata media

57yo

Età media

Gestione esperta: Il team dirigenziale di IDD è considerato esperto (durata media dell'incarico 4.5 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Mario Sznol	Strategic Advisory Board Member	5.9yrs	Nessun dato	Nessun dato
Olivier Martinez	Member of Supervisory Board	no data	Nessun dato	Nessun dato
Diane Mathis	Strategic Advisory Board	less than a year	Nessun dato	Nessun dato
Gilles Brisson	Independent Member of Supervisory Board	17.3yrs	€29.00k	0.090% € 124.2k
Sally Bennett	Independent Supervisory Board Member	2.4yrs	€45.00k	0.0031% € 4.3k
Jean-Yves Blay	Independent Member of Supervisory Board	6.8yrs	€29.00k	0.000060% € 82.6
Irina Staatz-Granzer	Independent Chairwoman of Supervisory Board	15.3yrs	€42.00k	0.031% € 42.7k
Pascale Boissel	Independent Vice Chairperson of the Supervisory Board	4.4yrs	€60.00k	0.0012% € 1.7k
Miriam Merad	Chairman of Strategic Advisory Board	5.9yrs	Nessun dato	Nessun dato
Veronique Chabernaud	Independent Member of Supervisory Board	9.5yrs	€48.00k	0.00082% € 1.1k
Katy Rezvani	Strategic Advisory Board	less than a year	Nessun dato	Nessun dato
Aurelien Marabelle	Strategic Advisory Board Member	5.9yrs	Nessun dato	Nessun dato

5.9yrs

Durata media

62.5yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di IDD sono considerati esperti (durata media dell'incarico 5.8 anni).

Innate Pharma Gestione

Gestione criteri di controllo 4/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Innate Pharma SA Announces Board Changes

Innate Pharma Announces Resignation of Mondher Mahjoubi as Chief Executive Officer, Effective as of January 2024

Innate Pharma S.A. Announces Executive Changes

Innate Pharma S.A. Announces Supervisory Board Changes

Innate Pharma S.A., Annual General Meeting, May 28, 2021

Innate Pharma S.A. Receives Prime Designation from the European Medicines Agency for Lacutamab in Sézary Syndrome

Recent updates

Innate Pharma SA Announces Board Changes

Araris Biotech AG entered into an agreement to acquire ADC Transglutaminase Conjugation Technology Patents Portfolio from Innate Pharma S.A. (ENXTPA:IPH).

First half 2024 earnings released: €0.31 loss per share (vs €0.021 profit in 1H 2023)

New minor risk - Profitability

New minor risk - Share price stability

Innate Pharma and Sanofi Shares Updated Results from the Sanofi Developed Blood Cancer Phase 1/2 1/2 SAR443579/IPH6101 Trial

New minor risk - Profitability

No longer forecast to breakeven

Innate Pharma SA Presents Positive Results from TELLOMAK Phase 2 Study with Lacutamab in Mycosis Fungoides

Innate Pharma Announces Advancement of Sanofi-Developed NK Cell Engager SAR443579 / IPH6101 Progressing to Phase 2 for Blood Cancer Patients

Innate Pharma S.A. Presents at AACR 2024 Preclinical Efficacy of Its Pre-IND Drug Candidate IPH45, a Novel Nectin-4 Antibody Drug Conjugate

Forecast to breakeven in 2026

Full year 2023 earnings released: €0.094 loss per share (vs €0.73 loss in FY 2022)

Innate Pharma S.A. Announces First Patient Dosed in Phase 1/2 Study of IPH6501 in Relapsed /Refractory B-Cell Non-Hodgkin’s Lymphoma

Innate Pharma S.A. has filed a Follow-on Equity Offering in the amount of $75 million.

Innate Pharma Announces Resignation of Mondher Mahjoubi as Chief Executive Officer, Effective as of January 2024

Innate Pharma Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab in Patients With Sézary Syndrome at ASH 2023

Innate Pharma S.A. Announces New Clinical Data for Lacutamab and SAR443579/ IPH6101 at ASH 2023

Innate Pharma S.A. to Report Q2, 2024 Results on Sep 12, 2024

New minor risk - Share price stability

Innate Pharma S.A. Provides Update on Lacutamab Clinical Program

Innate Pharma Announces Encore Presentation of Interim Results of Phase 2 TELLOMAK Study With Lacutamab With Updated Olsen 2022 Criteria at the EORTC Cutaneous Lymphoma Tumour Group Annual Meeting 2023

First half 2023 earnings released: EPS: €0.021 (vs €0.08 in 1H 2022)

Innate Pharma S.A. Announces Executive Changes

Innate Pharma SA Announces First Patient Dosed in SAR'514 / IPH6401 Phase 1/2 Clinical Trial in Relapsed/Refractory Multiple Myeloma

Innate Pharma SA Announces First Patient Dosed in SAR'514 / IPH6401 Phase 1/2 Clinical Trial in Relapsed/Refractory Multiple Myeloma

Innate Pharma S.A. Announces First Patient Dosed in Matisse Trial of IPH5201 in Early Stage Lung Cancer

Innate Pharma Sa Highlights Increased Lacutamab Clinical Activity from Interim Results of Phase 2 Tellomak Study with Updated Olsen Criteria

Innate Pharma S.A. Highlights Proprietary Tetra-Specific Anket Nk Cell Engager Iph6501 At the Eha 2023 Congress

Innate Pharma S.A. Announces SAR’579 / IPH6101 Receives FDA Fast Track Designation in the US for the Treatment of Hematological Malignancies

Innate Pharma Highlights Phase 1/2 Dose Escalation Safety and Preliminary Efficacy of Sanofi Developed First NK Cell Engager SAR'579 / IPH6101 in R/R AML

No longer forecast to breakeven

Innate Pharma SA Announces Publication of Preclinical Data with a Trifunctional NK Cell Engager in Acute Myeloid Leukemia in Nature Biotechnology

Innate Pharma S.A. Presents Data From Ongoing Phase 2 TELLOMAK Trial Demonstrating Clinical Activity of Lacutamab in Advanced Sézary Syndrome at ASH 2022

Innate Pharma S.A. to Report First Half, 2023 Results on Sep 14, 2023

Innate Pharma SA Presents Data From Ongoing Phase 2 TELLOMAK Trial Demonstrating Clinical Activity of Lacutamab in Advanced Mycosis Fungoides

First half 2022 earnings released: EPS: €0.08 (vs €0.30 loss in 1H 2021)

Innate Pharma Provides Update on AstraZeneca-Sponsored INTERLINK-1 Phase 3 Study

Innate Pharma Announces IPH5201 Phase 2 Study in Lung Cancer

Innate Pharma S.A. Announces Supervisory Board Changes

Innate Pharma Sa Announces the First Patient Was Dosed in A Phase 1/2 Clinical Trial

Innate Pharma SA Announces That Data from the Phase 2 Expansion Cohort

First half 2021 earnings released: €0.30 loss per share (vs €0.13 loss in 1H 2020)

Innate Pharma SA Announces Update on Avdoralimab Phase 2 Force Trial in COVID-19 Patients With Severe Pneumonia

Innate Pharma Presents Preliminary Data from TELLOMAK Trial Showing Clinical Response for Lacutamab in Mycosis Fungoides

Innate Pharma Presents New Data on Next-Generation NK Cell Engager Platform at FOCIS 2021 Annual Meeting

Innate Pharma S.A. Announces New Lacutamab Data from Tellomak Trial in Oral Presentation at Upcoming 16th International Conference on Malignant Lymphoma

Member of Supervisory Board Marcus Schindler has left the company

Full year 2020 earnings released

Full year 2020 earnings released

Innate Pharma S.A. Advances Lacutamab Clinical Development Program

Innate's First NK Cell Engager Selected by Sanofi as Drug Candidate for Development

Rosen Law Firm Reminds Innate Pharma S.A. Investors of Important December 22 Deadline in Securities Class Action

Innate Pharma S.A., Annual General Meeting, May 28, 2021

Innate Pharma Receives Prime Designation from the European Medicines Agency for Lacutamab in Sézary Syndrome

Innate Pharma S.A. Receives Prime Designation from the European Medicines Agency for Lacutamab in Sézary Syndrome

Innate Pharma Launches HopeConnectLearn: A New Online Resource for Hairy Cell Leukemia Patients

New 90-day low: €3.01

New 90-day low - €3.59

First half earnings released

New 90-day low - €5.11

AMMINISTRATORE DELEGATO

Mandato

Compensazione

Gruppo dirigente

Durata media

Età media

Membri del Consiglio di amministrazione

Durata media